Roche is a pharmaceutical and diagnostics company that focuses on improving people’s lives.
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the largest pharmaceutical company in the world, and the leading provider of cancer treatments globally.
The company controls the American biotechnology company Genentech, which is a wholly-owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based companies Ventana and Foundation Medicine. Roche’s revenues during fiscal year 2020 were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares. Roche is one of the few companies increasing their dividend every year, for 2020 as the 34th consecutive year. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
As a result of the $7.1 billion transaction, Roche will get the rights to develop and distribute RVT-3101 in the US and Japan. The deal is expected to be completed at the end of this year or in the first quarter of 2024.
Roche posted good numbers for Q1 2022 and expects a stable outlook for the rest of the year despite waning Covid medicine sales.
With the antibody tests which involve a blood draw and secures the Emergency Use Authorization from the US Food and Drug Administration (FDA), one will be able able to ascertain his antibody levels before and after receiving the COVID-19 vaccine shots.
